An Australian stem cell and regenerative medicine company

Renal transplantation

The clinical opportunity

Renal transplantation is a treatment for end-stage kidney disease, where the kidneys are no longer able to function and transplant into the patient of a donor kidney is required to eliminate patient’ reliance on dialysis.  To prevent the risk of rejection of the donor organ lifelong immunosuppression is typically required; the use of such drugs is associated with significant morbidity.

The data

Cymerus™ MSC treatment in a preclinical transplant model demonstrated immunoregulatory effects expected to prevent or reduce organ transplant rejection [1].

Proposed clinical trial

Building on the very encouraging pre-clinical data Cynata is presently developing plans to commence a clinical trial in renal transplant patients, expected to commence in 2021.

[1] Khan M.A., et al Stem Cell Res Ther. 2019;10(1):290.